What Dottikon Es does

Dottikon ES Holding AG is a Swiss specialty chemical contract development and manufacturing organization (CDMO) headquartered in Dottikon, Canton Aargau. Founded in 1913 as Schweizerische Sprengstoff-Fabrik AG, the company has evolved over 110 years into a focused exclusive-synthesis provider, operating today with more than 800 employees from a single 600,000 m² site in Switzerland. Approximately 90% of net sales derive from custom manufacturing of active pharmaceutical ingredients (APIs), with the balance from proprietary performance chemicals and the Dottisol isosorbide-dimethyl-ether line.

The company's core technology platform is built around four differentiated capabilities: hazardous reactions (including azide chemistry, oxidations, hydrogenations, and alkylations, supported by 14 proprietary safety tests); low-temperature chemistry down to -100 °C; high-pressure chemistry up to 50–100 bar using a library of 400+ catalysts; and continuous processing in micro and tubular flow reactors with throughput up to 2,000 kg/hour. Production infrastructure comprises 450 m³ of reactor volume across stainless-steel, glass-lined, and Hastelloy C22 vessels, complemented by an on-site high-temperature waste incineration facility operating above 1,100 °C. The firm runs 33 simultaneous development projects and has completed more than 3,400 projects over its history, scaling from grams to multi-tons under cGMP.

Dottikon's revenue model is B2B enterprise custom manufacturing on a quote-based, multi-year contract basis. Go-to-market combines a direct business development team covering Europe and North America with regional channel representatives in Spain (Azelis), India (Chemet), Japan (DKSH), and Taiwan (Tong Sing Chemicals). The customer base is concentrated in the pharmaceutical and biotech verticals, with regulatory coverage spanning FDA, EMA, and Swissmedic approvals. Listed on the SIX Swiss Exchange since March 2005 (ticker DESN), the company was spun off from EMS-CHEMIE HOLDING AG, which had owned it since 1987.

Name

Dottikon Es

Legal name

Dottikon ES Holding AG

Website

https://dottikon.com

Company type

Public

Founded year

1913

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Dottikon ES Holding AG is a Swiss specialty chemical CDMO that manufactures custom active pharmaceutical ingredients and performance chemicals from a single 600,000 m² site in Dottikon, serving global pharmaceutical, biotech, and chemical customers with hazardous-reaction, low-temperature, high-pressure, and continuous-processing capabilities.

Ownership category

akta.pro rank

Product category

Custom API and Chemical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC)

Keywords

• Custom chemical manufacturing
• Active pharmaceutical ingredients
• Exclusive synthesis services
• Hazardous reaction chemistry
• Contract development manufacturing

Headquarters

HQ city

Dottikon

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Exclusive Synthesis / Custom Manufacturing: Custom chemical manufacturing services from grams to multi-tons, including routefinding, process design, process development, small-scale and pilot production, manufacturing, qualification and validation services. This is the primary revenue stream.
2. Active Pharmaceutical Ingredients (APIs): Production of APIs under cGMP conditions. DOTTIKON has over 40 years of experience in API manufacturing. Approximately 90% of net sales come from APIs. Services include preformulation, blending, DMF/ASMF submission and maintenance.
3. Performance Chemicals: Proprietary high-grade performance chemicals including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides for industrial applications.
4. Catalog Products: Standard chemical building blocks and intermediates including amines, anilines, azaindoles, benzimidazoles, and other specialized compounds.
5. Waste Treatment Services: High-temperature incineration and environmental waste disposal services for hazardous waste, handling quantities from 10 kg to several thousand tons per year.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Dottikon ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) under cGMP conditions for the world's leading chemical, biotech, and pharmaceutical industry customers. Its core service is Exclusive Synthesis — a fully integrated custom manufacturing offering from grams to multi-tons that spans routefinding, process design, process development, small-scale and pilot production, commercial manufacturing, and qualification/validation. Approximately 90% of net sales are derived from API manufacturing executed from a single 600,000 m² site in Dottikon, Switzerland.

Product overview

Dottikon ES is a chemical contract manufacturing company offering a portfolio of products and services centered on exclusive synthesis of active pharmaceutical ingredients (APIs) and performance chemicals. The core offerings include Exclusive Synthesis services, Active Pharmaceutical Ingredients (FDA and EMA approved), Performance Chemicals, and the proprietary Dottisol product (isosorbide dimethyl ether). Supporting services include Project Management, Quality Management (ISO 9001/cGMP), Nitrosamine Risk Assessment, Containment, and Recycling & Waste Treatment. The company operates its manufacturing at a single site in Switzerland using core technologies including Hazardous Reactions (110+ years experience), Low-Temperature Chemistry (down to -100°C), High-Pressure Chemistry (up to 50 bar), and Continuous Processing (up to 2,000 kg/hour throughput).

Differentiator

Problem solved

Functional benefit

Brands

• Dottisol: High purity, non-GMO isosorbide dimethyl ether (CAS 5306-85-4) - a solubility enhancer used in cosmetics, pharma, and agro applications.

Products and services

• Exclusive Synthesis Custom manufacturing services for chemical synthesis from grams to multi-tons, covering routefinding, process design, process development, small-scale and pilot production, commercial manufacturing, qualification and validation. Designed for global pharmaceutical, biotech, and chemical industry customers needing hazardous or complex chemistry under cGMP.
• Active Pharmaceutical Ingredients (APIs) FDA- and EMA-approved production of APIs under cGMP, manufactured from kilograms to multi-tons under ICH guidelines. Includes preformulation, blending, DMF/ASMF submission and maintenance. Represents approximately 90% of net sales.
• Performance Chemicals Proprietary high-grade performance chemicals including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides for polymer, adhesive, resin, surface modification, and composite applications. Sold to industrial customers in the chemical sector.
• Dottisol Registered-trademark high-purity, non-GMO isosorbide dimethyl ether (CAS 5306-85-4) used as a solubility enhancer in cosmetics, pharma, and agro applications and as a performance additive in various industries.
• Catalog Products Standard catalog offering of high-quality chemical building blocks and intermediates, including amines, anilines, azaindoles, benzimidazoles, boronic building blocks, chiral compounds, heterocycles, nitrate esters, and nitroaromatic compounds for research and industrial buyers.
• Nitrosamine Risk Assessment Product-specific and systematic theoretical evaluation of nitrosamine risk level based on EMA and FDA guidelines, including confirmatory testing using GC-MS-TQ and LC-MS equipment. Targeted at pharmaceutical customers needing regulatory risk assessments of APIs and intermediates.
• Recycling & Waste Treatment High-temperature thermal waste recovery and environmental waste-disposal service for hazardous waste, accepting quantities from 10 kg to several thousand tons per year. Includes a wastewater pre-treatment step with activated carbon adsorption.

Quantifiable outcome

• Over 3,400 projects completed
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• SYSTAGcoreStrategic or Co-development Partner · 30 January 2026SYSTAG is DOTTIKON ES' associated company. In January 2026, Büchiglas took a strategic stake in SYSTAG. SYSTAG appears to be a technology or systems partner related to DOTTIKON's operations.
• BüchiglascoreStrategic or Co-development Partner · 30 January 2026Büchiglas took a strategic stake in SYSTAG (DOTTIKON ES' associated company) in January 2026. This represents a strategic investment in DOTTIKON's associated technology company.
• Azelis España, S.A.minorChannel Partner/ Reseller/ DistributorRegional representative for Spain, located at WTC Almeda Park, Cornellà de Llobregat, Barcelona, Spain.
• ChemetminorChannel Partner/ Reseller/ DistributorRegional representative for India, located at Span Centre, Mumbai, India.
• DKSH Japan K.K.minorChannel Partner/ Reseller/ DistributorRegional representative for Japan with offices in Tokyo (Minato-ku) and Osaka (Chuo-ku), Japan.
• Tong Sing Chemicals Co., Ltd.minorChannel Partner/ Reseller/ DistributorRegional representative for Taiwan, located in Taipei, Taiwan.

Scale indicators18 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hovione: Portugal-origin specialty CDMO with strong focus on complex small-molecule chemistry and particle engineering. Direct peer in custom API space, particularly where hazardous and complex chemistry is required, similar to Dottikon's positioning.
• Bachem: Swiss peptide and oligonucleotide CDMO. Comparable as a publicly listed Swiss specialty CDMO serving pharma, though focused on peptide chemistry rather than small-molecule hazardous chemistry.
• Carbogen Amcis: Swiss-headquartered CDMO specializing in API development and highly potent compounds. Highly comparable niche to Dottikon's hazardous-reaction and high-potency containment capabilities.
• Recipharm: European CDMO with API and finished-dose capabilities. Overlaps directly with Dottikon's custom manufacturing for pharma customers and is a relevant comparable for European CDMO unit economics.
• Lonza Group: Swiss-headquartered global CDMO with large-scale API and small-molecule manufacturing. Direct competitor to Dottikon's Swiss specialty chemical and API custom manufacturing, particularly in the small-molecule and haz-chem niches, though Lonza operates across many modalities and global sites.
• Siegfried Holding: Swiss CDMO with end-to-end API and intermediates production. Most closely comparable size and business model to Dottikon as a publicly listed Swiss mid-cap custom manufacturer focused on small-molecule APIs.
• Cambrex: US-based small-molecule API and intermediates CDMO. Direct peer offering custom manufacturing and process development services comparable to Dottikon's exclusive synthesis platform, with a broader North-American geographic footprint.

Broad incumbents

• Catalent: US-listed CDMO with broad formulation, biologic, and drug-delivery capabilities. Overlaps with Dottikon's custom manufacturing role but is more weighted toward finished dosage forms and biologics than small-molecule API chemistry.
• Thermo Fisher Scientific Pharma Services: Large diversified pharma services platform with substantial API/CDMO offerings (including Patheon). Broad incumbent competing with Dottikon across multiple service categories, though not specialized exclusively in hazardous-reaction small-molecule APIs.

Regional players

• ScinoPharm Taiwan: Taiwan-based API manufacturer with cGMP capabilities serving global pharma. Comparable as an API producer and a regional player serving Asia/Pacific customers—a geography where Dottikon currently has only ~1% revenue exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dottikon-exclusive-synthesis-ag

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dottikon Es